ArticleHaematologica2019
Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.PloS one · 2021Pooled it
- Acute hemophagocytic lymphohistiocytosis in a patient treated for stone removal via percutaneous nephrolithotomy: a case report and literature review.International journal of surgery case reports · 2026Article
- Article
- Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference Center.Acta haematologica · 2026Article
- An Unusual Presentation of Secondary Hemophagocytic Lymphohistiocytosis With Melena: A Case Report.Cureus · 2026Article
- Distinct Clinical and Prognostic Features of Acute and Chronic Active Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adults: A Scoping Review.ImmunoTargets and therapy · 2026Review
- Integration of Boruta algorithm and latent class analysis for risk factors of 30-day mortality in pediatric hemophagocytic lymphohistiocytosis based on peripheral blood indicators.Frontiers in pediatrics · 2026Article
- Long-Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report.Case reports in hematology · 2026Article
- Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.Lupus science & medicine · 2025Observational
- Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis.The American journal of tropical medicine and hygiene · 2025Article
- Article
- Article
- Oncogenic Potential of Epstein-Barr Virus in NK and NKT Cells Contribute to the Rapid Deterioration of Hemophagocytic Lymphohistiocytosis.Journal of medical virology · 2025Article
- Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis.European journal of haematology · 2025Article
- Article
- Clinical characteristics and prognostic factors in patients with fever of unknown origin who developed secondary haemophagocytic lymphohistiocytosis.Annals of hematology · 2025Article
- Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH).Orphanet journal of rare diseases · 2025Review
- Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.Haematologica · 2025Article
- Fungal-Induced Hemophagocytic Lymphohistiocytosis: A Literature Review in Non-HIV Populations.Journal of fungi (Basel, Switzerland) · 2025Review
- Flow cytometric analysis of the immune cell subsets in adult hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis is an overwhelming systemic inflammatory process that is life-threatening if not treated appropriately. We analyzed prognostic factors in patients with secondary hemophagocytic lymphohistiocytosis excluding malignancy. In this retrospective study, we analyzed 126 adult cases between 2001 and 2017. Treatment was based on dexamethasone with or without etoposide and cyclosporine. Patients who achieved a complete response by 4 weeks were defined as early stable responders, those who failed to achieve a complete response but showed continuous improvement until 8 weeks were defined as late responders, and those whose conditions waxed and waned until 8 weeks were defined as unstable responders. Patients with hemophagocytic lymphohistiocytosis caused by Epstein-Barr virus had a worse 5-year overall survival compared to those whose disease was secondary to autoimmune disease, other infections, or unknown causes (25.1%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.